Heterocyclic amines and arylamine N-acetyltransferase 2 polymorphism in pathogenesis of insulin resistance. by Walls, Kennedy M
University of Louisville 
ThinkIR: The University of Louisville's Institutional Repository 
Electronic Theses and Dissertations 
1-2021 
Heterocyclic amines and arylamine N-acetyltransferase 2 
polymorphism in pathogenesis of insulin resistance. 
Kennedy M. Walls 
University of Louisville 
Follow this and additional works at: https://ir.library.louisville.edu/etd 
 Part of the Heterocyclic Compounds Commons 
Recommended Citation 
Walls, Kennedy M., "Heterocyclic amines and arylamine N-acetyltransferase 2 polymorphism in 
pathogenesis of insulin resistance." (2021). Electronic Theses and Dissertations. Paper 3622. 
https://doi.org/10.18297/etd/3622 
This Master's Thesis is brought to you for free and open access by ThinkIR: The University of Louisville's 
Institutional Repository. It has been accepted for inclusion in Electronic Theses and Dissertations by an authorized 
administrator of ThinkIR: The University of Louisville's Institutional Repository. This title appears here courtesy of 
the author, who has retained all other copyrights. For more information, please contact thinkir@louisville.edu. 
 
HETEROCYCLIC AMINES AND ARYLAMINE N-ACETYLTRANSFERASE 2 
POLYMORPHISM IN PATHOGENESIS OF INSULIN RESISTANCE 
 
By 
Kennedy M. Walls 
B.S. Chemistry, track in biochemistry, University of Louisville, 2019 
 
A Thesis submitted to the faculty of the School of Medicine of the University of 
Louisville in partial fulfillment of the requirements for the degree of  
 
Master of Science in Pharmacology and Toxicology 
 
Department of Pharmacology and Toxicology 











Copyright 2021 by Kennedy M. Walls 



























HETEROCYCLIC AMINES AND ARYLAMINE N-ACETYLTRANSFERASE 2 
POLYMORPHISM IN PATHOGENESIS OF INSULIN RESISTANCE 
 
By 
Kennedy M. Walls 
B.S. Chemistry, track in biochemistry, University of Louisville, 2019 
 
A Thesis approved on 
 
April 15, 2021 
 




David Hein, Ph.D. 
 
_____________________________ 
Kyung Hong, Ph.D. 
 
_____________________________ 
Daniel Conklin, Ph.D. 
 
_____________________________ 
Bradford Hill, Ph.D. 
 
_____________________________ 





I dedicate this thesis to my mother and sister for supporting me in my academic 


















I’d like to thank my lab members, Mariam Habil, Dr. Raul Salazar-
Gonzalez, Dr. James Wise, and Mark Doll for their help and guidance with my 
work. I’d also like to thank my mentors, Drs. Kyung Hong and David Hein, for 
their patience and support with my project. I offer special thanks to my committee 
members, Dr. Joshua Hood, Dr. Bradford Hill, and Dr. Daniel Conklin, for their 
insight and suggestions. Lastly, I’d like to express gratitude to my family and 















HETEROCYCLIC AMINES AND ARYLAMINE N-ACETYLTRANSFERASE 2 
POLYMORPHISM IN PATHOGENESIS OF INSULIN RESISTANCE 
 
Kennedy M. Walls 
 
April 15, 2021 
 
  
 Heterocyclic amines (HCAs) are formed when cooking meats at high 
temperatures or for long periods of time, and their major metabolic pathway 
includes hepatic N‑hydroxylation by CYP1A2 followed by O-acetylation by N-
acetyltransferase 2 (NAT2). NAT2 is a highly polymorphic gene involved in 
metabolism of drugs and xenobiotics, and its single nucleotide polymorphisms 
(SNPs) produce phenotypes characterized as slow, intermediate, or rapid 
acetylator. Recent studies have documented associations between HCAs and 
insulin resistance and between certain NAT2 phenotypes and insulin resistance. 
In this study, we demonstrated that NAT2 activity and exposure to certain HCAs 
may alter cellular glucose and lipid homeostasis. Additionally, these results 
demonstrate changes in sensitivity to insulin following exposure to some HCAs. 
These findings are significant because they indicate a genetic component (NAT2 
polymorphism) and an environmental component (dietary HCA exposure via 
consumption of cooked meat) in the pathogenesis of insulin resistance in 
hepatocytes of human origin.  
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Arylamine N-acetyltransferases (NATs) 
Arylamine N-acetyltransferases (NATs) are enzymes that metabolize 
xenobiotics and drugs, and they are known to play a role in detoxification of 
many compounds [1]. Specifically, they add an acetyl group from acetyl 
coenzyme A (CoA) to arylamines and arylhydrazines, which may detoxify or 
bioactivate the compound. Two NAT genes (NAT1 and NAT2) have been 
identified and characterized in humans. NAT1 and NAT2 are similar in structure, 
but they differ in substrate selectivity and physiological function [2]. For example, 
NAT1 demonstrates an affinity for p-aminobenzoic acid (PABA), and NAT2 
demonstrates affinity for sulfamethazine [4]. NAT1 is expressed ubiquitously, 
while NAT2 expression is restricted to the liver and gastrointestinal tract [8, 9]. 
The importance of NAT2’s substrate selectivity and organ-specific expression will 
be further discussed in later sections. 
NAT1 and NAT2 function as catalysts for both N-acetylation and O-
acetylation of drugs, aromatic amines, and heterocyclic amines. NAT2 catalyzes 
N-acetylation of drugs like sulfamethazine, hydralazine and dapsone, and this is 
usually a deactivation [5]. Following oxidation by cytochrome P450 (CYP450), 
NAT2 catalyzes O-acetylation of heterocyclic amines like 2-amino-1-methyl-6-
phenylimidazo[4,5-b]pyridine (PhIP), 2-amino-3,4-dimethylimidazo[4,5-f]quinoline 
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(MeIQ), and 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline (MeIQx) found in 
cooked meats, and this is usually an activation process [6]. 
 
NATs and metabolism 
NATs catalyze both N-acetylation and O-acetylation of drugs, aromatic 
amines, and heterocyclic amines. Figure 1 illustrates the reaction pathways 
undergone by aromatic and heterocyclic amines [34]. N-conjugation of NATs, 
UDP-glucuronosyltransferases (UGTs), or sulfotransferases (SULTs) produces 
non-toxic, stable N-acetates, N-glucuronides, and N-sulfates, respectively. In 
contrast, N-oxidation of arylamines or N-acetamides, mediated by 
cytochrome P450 1A2 (CYP1A2) or by prostaglandin H synthase (PHS) 
peroxidase, is a vital step in metabolic activation, generating more reactive 
hydroxylamines or hydroxamic acids [35, 36].  Further N-acetylation, O-
acetylation and intramolecular N,O-acetyltransfer alters levels of chemically 
unstable acetoxy esters and N-acetyl-acetoxy esters, which are considered the 
ultimate carcinogens that will spontaneously decompose to electrophilic DNA- or 
protein-binding nitrenium ions [37]. 
In addition to NAT’s ability to catalyze acetyl CoA-dependent conjugation on 
nitrogen atoms to produce arylamides and hydrazides, NATs can also 
mediate O-acetylation (OAT) and, to a lesser extent, N,O-acetyltransfer (NOAT) 
reactions, as demonstrated in Figure 1 below [38]. SULTs and UGTs can also 
biotransform hydroxylamines and hydroxamic acids formed by NAT/CYP1A2 into 
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sulfate or glucuronide esters that decompose to nitrenium ions [39, 40]. Lastly, 
microsomal deacetylases (DAC) can reverse acetylation reactions by influencing 
levels of substrates for activating pathways. Tumorigenicity of 2-
acetylaminofluorene (AAF) may require its deacetylation to the arylamine [41], 
which is then presumably activated by pathways previously described. 
 
 





To provide an example of NAT2 metabolism, NAT2’s N-acetylation of 
aromatic amines like 4-aminobiphenyl (ABP) is a detoxification process. N-
acetylation competes with P450-catalyzed N-hydroxylation followed by O-
acetylation of N-hydroxy-amine (catalyzed by NAT2), which generates acetoxy-
derivatives that are highly unstable. This leads to the formation of arylnitrenium 
ions that bind to DNA, resulting in mutagenesis and carcinogenesis [18]. 
Subsequently, NAT allelic variations producing various acetylator phenotypes 
impact the extent of these reactions’ effects (see discussions below). 
 
NAT Single Nucleotide Polymorphisms 
 Both NAT1 and NAT2 exhibit single nucleotide polymorphisms (SNPs), 
and NAT2 genotypic variants result in slow, intermediate, and rapid acetylator 
phenotypes [14, 15]. SNPs occur when a DNA sequence variation occurs due to 
a single nucleotide substitution, producing varying alleles within a locus. For any 
given SNP, the SNP can occur in a coding region but not result in a change in 
amino acid; it can occur in a coding region and result in an amino acid change; it 
can occur in a regulatory region resulting in a change in gene expression; or it 
can occur in a region between genes [3]. In the context of NAT2 SNPs discussed 
here, these SNPs occur in the coding region of the gene, resulting in amino acid 
changes and thus generating different alleles that produce slow, intermediate, or 
rapid phenotypes [3].  
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There are 28 NAT1 alleles and 108 NAT2 alleles, and allelic frequencies differ 
among different populations [10,11]. As mentioned, these SNPs are associated 
with varying enzymatic activity and stability, which will be further described in the 
following sections [12-14].  To mention some of the more common NAT2 alleles, 
NAT2*4 makes up 20–25% of alleles in the population study and is thus often 
considered the reference allele, and this is a rapid acetylator phenotype. The 
reference allele occurs at a somewhat higher frequency in African Americans 
(36–41%) and Hispanics (41%) [27, 28]. Reference allele frequency is highest in 
Asians (50% in Chinese and 70% in Japanese) [29-33]. The effects of the rapid 
acetylator phenotype of this reference allele will be discussed in the following 
section. 
 An additional frequent NAT2 allele, NAT2*5 and its subtypes, were most 
frequent among Caucasians (44%), Gabonese (41%), Hispanics, and those of 
African descent (25–27%) [26]. This variant is associated with the slow 
acetylation phenotype, in contrast to the reference allele, which generates a rapid 
acetylator phenotype. NAT2*6 was distributed evenly across ethnic groups, while 
NAT2*7 was more prevalent among Asians. Although only a select few of the 
NAT2 allelic variation have been mentioned here, it should be noted that slow 
acetylator phenotype is likely not homogeneous, but rather that multiple slow 
acetylator phenotypes exist, and these result from different mechanisms inferred 
by various SNPs and haplotypes [14]. Thus, there are varying degrees of slow 




NAT2 SNPs and drug toxicity or cancer risk 
Increased risk for drug toxicity and cancer are associated with different NAT2 
genotypes and phenotypes [15]. For example, people with the slow NAT2 
phenotype have an increased risk of isoniazid-induced liver injury relative to 
those with the rapid NAT2 phenotype [16]. Isoniazid is a drug used for the 
treatment and prevention of tuberculosis, but treatment had frequently been 
compromised by isoniazid-induced hepatotoxicity and liver failure [95]. A 
previous study found that the incidence of isoniazid-induced hepatotoxicity 
differed among rapid (2.9%), intermediate (9.8%), and slow (22%) NAT2 
acetylators [95]. Slow acetylators are significantly more likely to experience 
hepatotoxicity from isoniazid treatment for tuberculosis than rapid acetylators 
because slow acetylators retain a higher plasma concentration of the drug for an 
extended time [96]. 
 Additionally, carriers of the slow acetylator genotype are correlated with 
greater adverse health responses after hydralazine treatment relative to rapid 
acetylators. Hydralazine is indicated in treatment of chronic hypertension, short-
term therapy of pregnancy-induced hypertension and eclampsia, and in therapy 
of hypertensive crisis [97,98]. A rare side effect of hydralazine, a systemic lupus 
erythematosus (SLE)-like syndrome, has been observed and can have serious 
adverse health consequences. Hydralazine treatment for hypertension is 
modified by acetylator phenotype following oral administration [99], and there is 
substantial evidence supporting a correlation between NAT2 acetylator 
phenotype or genotype and urine and plasma hydralazine concentrations. Like 
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the previously discussed drug isoniazid, slow acetylators are more likely to 
experience adverse effects of hydralazine because they maintain higher plasma 
concentrations of the drug for a longer period, and thus NAT2 genotype should 
be considered when dosing hydralazine. 
In addition to alterations in drug toxicity, both rapid and slow NAT2 acetylator 
phenotypes have been associated with increased risk of cancer in different target 
organs following arylamine exposure [21]. Rapid acetylators detoxify aromatic 
amines to a greater extent than slow acetylators via N-acetylation so they may be 
excreted from the body more quickly. However, following N-oxidation, the 
metabolites can undergo bioactivation via the O-acetylation pathway. The O-
acetylation pathway often leads to formation of arylnitrenium ions and DNA 
adducts, then carcinogenesis if DNA cannot be repaired. For this reason, slow 
NAT2 acetylation has been associated with higher risk of developing urinary 
bladder cancer due to decreased ability to detoxify aromatic amines by N-
acetylation [19, 20]. 
In contrast to urinary bladder cancer, the risk of colorectal cancer from well-
done cooked meat was higher among rapid NAT2 acetylators compared to slow 
acetylators resulting from increased rate of metabolism of heterocyclic amines 
(HCAs), carcinogens produced when cooking meat at high temperatures or until 
well-done [22-25]. Additionally, rapid acetylators are more prone to liver cancers 
following exposure to carcinogenic aromatic amines [35, 38, 39]. To elaborate on 
this paradoxical phenomenon, as mentioned previously, CYP450 mediates N-
hydroxylation followed by NAT2 O-acetylation of aromatic amines, resulting in a 
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carcinogenic metabolite. Since this metabolic process occurs in the liver, rapid 
acetylators are at greater risk of developing liver cancers [110]. However, in the 
case of urinary bladder cancer, N-hydroxylated aromatic amines exit the liver, 
unaltered by slow NAT2 acetylation, and reach the bladder, where DNA adducts 
are formed following an acid-catalyzed reaction with urothelial DNA [8]. 
Therefore, rapid NAT2 acetylation increases risk of liver cancer, while slow NAT2 
acetylation increases risk of urinary bladder cancer. These data indicate the 




Heterocyclic Amines (HCAs) 
HCA Structures and Classifications 
Heterocyclic amines (HCAs) are polycyclic aromatic molecules and known 
mutagens [42]. They are primarily formed in muscle foods including meats and 
fish, which provide precursors like creatinine, amino acids, and aldehydes [43-
45]. Cooking meats at high temperatures and for long periods of time including 
frying, grilling, and roasting cooking methods substantially enhance HCA 
formation [46-48]. 
More than 25 HCAs have been isolated from food samples and their 
structures defined, some of which will be described further in the following 
section [49]. All HCAs contain at least one aromatic structure and one 
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heterocyclic structure, and most of them contain an exocyclic amino group. The 
five-membered heterocyclic aromatic ring of one class of HCAs, the amino-
carbolines, is wedged between two six-membered aromatic rings. In contrast, 
another class of HCAs, aminoimidazo-azaarenes (AIAs), have an N-attached 
methyl group at the imidazole ring. Amino-carbolines, instead, either lack a 
methyl group entirely, or the methyl group is attached to a six-membered ring. 
Formation of different classes of mutagens from proteinaceous foods is 
determined by the critical heating temperature of 300 degrees Celsius [50]. 
Protein pyrolysates form above 300 °C, and these are characterized as 2-amino-
pyridine-mutagens, also known as amino-carbolines [51, 52]. Those formed 
below 300 °C are considered 2-amino-imidazole-type mutagens, also known as 
aminoimidazo-azaarenes (AIAs) [53]. Pyrolytic mutagens can be further divided 
into five groups, including pyridoindoles, pyridoimidazoles, phenylpyridines, 
tetraazafluoranthrene, and benzimidazole. AIAs are divided further into three 
groups, including IQ, 2-amino-3-methyl-imidazo[4,5-f]quinoxaline (IQx), and 
imidazopyridine.  
An additional method of classifying HCAs includes polarity. Polar HCAs 
include the IQ, IQx-type, and imidazopyridine type (AIAs), while nonpolar HCAs 
have a common pyridoindole or dipyridoimidazole moiety [54]. Polar HCAs are 
formed from amino acids, carbohydrates, and creatinine when a temperature 
between 150 and 250 °C is reached. Non-polar HCAs form at higher 
temperatures and are usually assigned as pyrolysis products of the amino acids 
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[53]. Figures 2 shows structures of common HCAs that are found most frequently 







Figure 2. Structures of common HCAs. Adapted from [42]. 
 
Formation of HCAs 
Formation of HCAs is a series of complex chemical reactions. The 
browning reaction was proposed by Maillard to account for the brown pigments 
and polymers produced from the reaction of the amino group of an amino acid 
and the carbonyl group of a sugar [16]. The Maillard reaction encompasses a 
network of reactions, including the formation of pyrazines, quinoxalines, and 
pyrido[3,4-d]imidazoles, which are involved in the formation of HCAs [46-48].  
 




Formation of amino-carbolines 
Amino acids or proteins are the precursors of amino-carbolines, and 
creatinine is not required for their formation. Therefore, they can be formed in 
foods originating from both animals and plants [43]. However, creatinine may 
function as an additional source of structural fragments. Free radical reactions 
occurring within drastic thermal environments is the suggested pathway for 
producing reactive fragments in amino-carbolines [56]. However, this hypothesis 
has yet to be fully investigated due to difficult manipulation of high temperatures 
required for experimental setups. 
 
Formation of aminoimidazole-azaarenes 
AIAs can be responsible for most of the mutagenic activity in cooked 
foods, especially in Western diets [57]. IQ- and IQx-type HCAs (structures found 
in Figure 2 above) and their methylated forms are likely formed from creatinine, 
sugars, free amino acids, and dipeptides through Maillard reaction and Strecker 
degradation upon heating [44, 58]. 
Creatinine was determined to be important for HCA formation because 
HCA yield was increased with the addition of creatinine to the surface of meat 
prior to frying it [59]. It was demonstrated that cyclization and water elimination of 
creatinine formed the amino-imidazo structure of IQ and IQx, and the Maillard 
reaction between amino acids and hexose formed the Strecker degradation 
products like pyridines or pyrazines, which formed the remainder of the molecule, 
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likely by aldol condensation [43, 61]. While the reaction is favored at temperature 
above 100 °C, pyrazine and pyridine yield from Maillard reaction and Strecker 
degradation is still low [46]. This phenomenon was considered a factor for low 
HCA yield in foods and common model systems, making it difficult to investigate 
AIAs [60]. 
 
Metabolism of HCAs and cancer 
Meat consumption has been associated with increased risk of many 
common cancers, including prostate, lung, breast, and colon cancer [100-103]. 
Genetic variation in NAT2 has been suggested to modify the association of meat 
intake with some cancers through its influence on metabolism of HCAs [103]. 
Thus, epidemiological studies have reported inconsistent associations between 
dietary HCA intake via meat consumption and increased cancer risk, as NAT2 
allelic variations occur naturally in the sampled human population.  
Despite inconsistent epidemiological reports, HCAs are highly mutagenic 
in vitro and in vivo [104].  Additionally, when HCAs were fed in the diet, rodents 
developed cancers in many organs, including the colon, breast, and prostate, 
and one HCA produced hepatomas in monkeys [104]. Many HCAs require 
metabolic activation to result in carcinogenesis. The initial step of HCA 
metabolism and activation is the generation of N-hydroxy-HCA derivatives, and 
this is catalyzed by cytochrome P450, mainly isoenzyme CYP1A2. Further 
metabolism and activation is carried out by NAT2 and SULTs, which catalyze 
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esterification of N-hydroxy-HCAs, as previously described in the NATs 
metabolism section. The resulting products of these reactions are highly 
genotoxic and capable of direct interaction with DNA by adduct formation. HCA-
DNA adducts can cause errors in DNA replication and result in mutations, which, 
when not repaired, may contribute to carcinogenesis. In contrast, UDP-
glucuronosyltransferases and glutathione S-transferases are enzymes involved 
in detoxification of HCAs [103 – 105]. Balance between activation and 
detoxication processes of HCAs, together with genetically determined differences 
in HCA metabolism (from NAT2 SNPs), are crucial for the understanding of HCA-




Insulin is an endocrine peptide hormone that binds plasma membrane-
bound receptors in target cells to orchestrate an anabolic response to nutrient 
availability [64]. Insulin is made in the pancreas and secreted from cells called 
the Islets of Langerhans. These cells release a small amount of insulin into the 
body continuously and release surges of insulin in response to a rise in the blood 
glucose level. 
Insulin’s role in glucose homeostasis is characterized by insulin’s direct 
effects on skeletal muscle, liver, and white adipocytes. In skeletal muscle, insulin 
promotes glucose uptake by increasing glucose transport and glycogen 
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synthesis. In the liver, insulin stimulates glycogen synthesis, increases lipogenic 
gene expression, and decreases gluconeogenic gene expression. In white 
adipocyte tissue, insulin suppresses lipolysis and increases glucose transport 
and lipogenesis [64].  
 
Signaling Pathways 
There are 2 known insulin-signaling pathways, and they are presented in 
Figure 3 below. These pathways are activated by insulin binding to the insulin 
receptor (labeled as IR) at the plasma membrane. Insulin/receptor interaction 
activates an intrinsic tyrosine protein kinase, which auto-phosphorylates the 
receptor and downstream substrates. In the main pathway, proteins known as IR 
substrates (IRS) are the immediate downstream substrates, which activate a 
cascade of serine-protein kinases [67, 68]. Akt (protein kinase B) is a major 
division point with numerous downstream substrates that lead to a variety of 
physiological functions like regulation of energy homeostasis [69], and this 
pathway will be discussed further in the following sections. The alternate pathway 
(‘‘ras/mitogen-activated protein kinase’’) is a serine-protein kinase cascade as 
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well, and this pathway regulates transcription, cell growth and differentiation, and 
protein synthesis [69, 70]. 
Figure 3. Two insulin signaling pathways mediate actions of insulin. 
Adapted from [64]. 
  
Metabolic Syndrome and Insulin Resistance 
Metabolic syndrome is clinically defined by having at least 3 of the 
following conditions: hypertension, elevated fasting blood sugar, obesity, low 
high-density lipoprotein cholesterol, and elevated triglycerides [71]. An individual 
with metabolic syndrome is at an increased risk of complications including 
atherosclerosis, type II diabetes mellitus, heart attack, kidney disease, fatty liver, 
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vascular disease, and stroke [72, 73]. Many have argued that the underlying 
etiology of metabolic syndrome could be insulin resistance [73, 74].  
When higher insulin levels are required to achieve the same glucose-
lowering response previously described, a subject is considered insulin resistant. 
Plasma lipids, hormones and adipokines, and their respective signaling pathways 
regulate insulin sensitivity [79,80], and pathological resistance to insulin (or 
lowered insulin sensitivity) develops through multifaceted interactions of 
genotype and lifestyle (including exercise habits and diet) [75-78].  
Our understanding of the physiology of insulin resistance largely relates to 
defective insulin action at target cells. However, when insulin resistance affiliated 
with human type II diabetes was shown to involve both a right-shifted dose-
response curve to insulin and a decreased overall maximum insulin response, it 
was inferred that both receptor and “post-receptor” (insulin signal transduction) 
defects contribute to insulin resistance [75]. 
The pathophysiology of insulin resistance in skeletal muscle is well 
described and can be found in reference texts [64]. For the purposes of this text, 
we will instead focus on the pathophysiology of hepatic insulin resistance.  
 
Selective Hepatic Insulin Resistance 
The liver plays a crucial role in systemic regulation of glucose and lipid 
metabolism and aberrant hepatic insulin action is thought to be a primary factor 
in insulin resistance [89]. In individuals with a normal physiologic fasting state, 
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high glucagon-to-insulin ratio will decrease glucose consumption and shift the 
liver into glucose production by consuming stored glycogen (glycogenolysis) and 
from glucogenic precursors (gluconeogenesis) [90]. Following a meal, decreased 
glucagon and increased insulin levels signal the liver to increase glucose 
consumption, stop glucose production, and store excess nutrients in the form of 
glycogen and lipids [91]. In obese individuals or those with pathological insulin 
resistance, insulin fails to regulate hepatic metabolism, leading to excess 
production of glucose despite accelerated rates of lipid synthesis. This condition 
is known as selective hepatic insulin resistance [92]. 
 
Hepatic Insulin Signaling and Lipid Metabolism 
As previously mentioned, evidence has indicated that the 
phosphoinositide 3-phosphate kinase (PI3K)/Akt pathway is the primary signaling 
pathway that mediates insulin’s effects on anabolic metabolism [93]. Figure 4 
models the primary insulin signaling pathway in hepatocytes. 
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Figure 4. PI3K/Akt signaling in hepatocytes. Adapted from [89]. 
 
Insulin binds to the insulin receptor on the surface of the liver following a 
meal. The receptor recruits and activates IRS, which then activates PI3K [94]. 
PI3K phosphorylates PIP2 into PIP3 in a process that is opposed by PTEN. PIP3 
activates 3-phosphoinositide-dependent protein kinase 1 (PDK1), which 
phosphorylates Akt at Thr308. mTORC2 also phosphorylates Akt at Ser473 to 
fully activate Akt. Various pathways for controlling glucose and lipid homeostasis 
branch out from Akt. Glycogen synthesis is induced through Akt inhibition of 
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GSK3. Akt can also promote glycogen independent of GSK3 via activation of 
GYS2 by glucose-6-phosphate (G6P). Akt inhibition of TSC activates mTORC1, 
which then activates SREBP1c and GCK, resulting in phosphorylation of glucose 
to G6P. G6P feeds into glycolysis and glycogen synthesis. Additionally, G6P 
activates ChREBP, which activates lipogenesis along with SREBP1c. Akt inhibits 
FOXO1, causing inhibition of gluconeogenesis by suppressing expression of the 
proteins, such as glucose-6-phosphatase (G6PC) and phosphoenolpyruvate 
carboxykinase 1 (PCK1). Free fatty acids (FFAs) can also promote 
gluconeogenesis and be taken up by the liver and converted to acetyl-CoA, 
which activates pyruvate carboxylase and contributes to insulin resistance [89]. 
 
Mechanisms of Hepatic Insulin Resistance 
Insulin orchestrates a switch from glucose production to glucose uptake in 
the liver. This involves suppression of gluconeogenesis and glycogenolysis and 
the activation of glycogen synthesis. Suppression of gluconeogenesis involves 
acute and chronic processes. Rates of hepatic gluconeogenesis are increased in 
type II diabetes and are the cause of fasting hyperglycemia that defines the 
disease [119]. Chronic suppression of gluconeogenesis by insulin, better 
observed in fasting-refeeding studies than acute insulin stimulation studies, is a 
direct hepatocellular effect mediated by inhibition of the FOXO transcription 
factors, especially FOXO1.  
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Removal of the hepatic insulin receptor is associated with unrestricted 
FOXO1 activity, which is required to drive pathological gluconeogenesis [119]. 
This phenotype is also seen in mice with severe hepatic insulin resistance 
resulting from removal of hepatic Irs1 and Irs2, in which Foxo1 deletion 
normalizes glucose tolerance [120]. Mouse models of hepatic insulin resistance, 
like ob/ob and lipodystrophic mice, display increased G6pc expression, indicating 
increased FOXO1 activity [121]. However, hepatic insulin resistance of fat-fed 
rats is not accompanied by alterations in gluconeogenic enzyme content, arguing 
against a role for FOXO1-driven gluconeogenic gene transcription in genetically 
normal rodents [122]. Reducing hepatic Pck1 expression by 90% in mice caused 
only a ~40% reduction in gluconeogenic flux, suggesting that fluctuations in Pck1 
expression exert limited control over gluconeogenesis [123]. Lastly, a study of 
humans with type II diabetes found no increase in the hepatic expression of 
FOXO1 targets G6PC and PCK1, despite fasting hyperglycemia [124]. Thus, 
depression of FOXO1 can drive pathological gluconeogenesis in rodents, but 
there is no strong evidence that this is a functional mechanism for fasting 
hyperglycemia in typical human hepatic insulin resistance. The complex control 
of hepatic gluconeogenesis indicates transcriptionally mediated increases in 
gluconeogenic capacity may not be sufficient to drive gluconeogenesis in 
genetically normal subjects. Therefore, increased hepatic gluconeogenesis of 





Consumption of Cooked Meat Associated with Insulin Resistance 
Heterocyclic amines (HCAs), such as 2-amino-3,4-
dimethylimidazo[4,5-f]quinoline (MeIQ) and 2-amino-1-methyl-6-
phenylimidazo[4,5-b]pyridine (PhIP), represent a group of compounds that are 
mutagenic and are known human carcinogens [42 – 45]. HCAs are formed via 
condensation of creatinine with amino acids when meats are cooked at high 
temperatures or for long periods of time [42]. When ingested, HCAs are 
absorbed and rapidly distributed. The major metabolic pathway for HCAs 
includes hepatic N-hydroxylation by CYP1A2 followed by O-acetylation by 
arylamine N-acetyltransferase 2 (NAT2) [21]. This leads to formation of 
arylnitrenium ion, which results in DNA damage. Previously, studies on HCAs 
and exposure via cooked meat have focused on their carcinogenic potential and 
association to common cancers [109]. Recently, an epidemiological study found 
a novel link between HCA exposure via cooked meat consumption and insulin 
resistance [111]. High HCA intake was associated with increased prevalence of 
insulin resistance, even after the multivariate analysis was adjusted for saturated 
fatty acid and cholesterol intake. However, this epidemiological association has 
not yet been validated in cell or animal models.  
 
NAT2 and Insulin Resistance 
Arylamine N-acetyltransferase 2 (NAT2) is a highly polymorphic gene that 
catalyzes metabolism of arylamines, including HCAs. NAT2 plays key roles in 
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detoxification or activation of carcinogenic arylamines and xenobiotics by 
catalyzing acetyl coA-dependent biotransformation of arylamines to N-
arylacetamides [18]. Individuals can be categorized as rapid, intermediate or 
slow acetylators according to their combinations of NAT2 alleles, and NAT2 
phenotype has been shown to influence metabolism, and thus the efficacy and 
toxicity, of arylamine drugs such as sulfamethazine [2]. NAT2 acetylator 
phenotype is associated with increased risk for colorectal cancer following 
exposure to HCAs [22 – 24]. 
Recently, certain genetic variants/polymorphisms of NAT2 have been 
linked to insulin resistance, high serum triglyceride, and coronary artery disease 
as well as high fasting plasma glucose level [112 – 116]. Analysis of Nat1-
knockout (homolog of human NAT2) mice revealed that Nat1 deficiency leads to 
development of insulin resistance and metabolic defects at the systemic level, 
supporting the previously unrecognized role of NAT2 in regulating metabolism 
and insulin sensitivity [117 – 118]. However, it is currently unknown how NAT2 
influences cellular metabolism and insulin sensitivity. 
 With newly documented associations between dietary HCA intake and 
insulin resistance and between NAT2 polymorphisms and insulin resistance, it is 
important we explore the novel link between HCA exposure to pathogenesis of 
insulin resistance in cell culture and animal models, and that we investigate the 
role of NAT2-mediated metabolism in this process. In the current study, we will 
analyze effects of HCAs and NAT2 phenotypes on insulin sensitivity in 
hepatocytes of human origin. Our results indicate that HCAs may directly induce 
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insulin resistance in human hepatocytes, and that NAT2 phenotype may impact 
sensitivity to insulin in human hepatocytes.  
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MATERIALS AND METHODS 
Source and Processing of Cryopreserved human hepatocytes 
Cryopreserved human hepatocytes were obtained from BioIVT and were stored 
in liquid nitrogen until use. Hepatocyte samples were collected from consenting 
donors under IRB approved protocols at the FDA licensed donor center at BioIVT 
(http://www.bioivt.com/). Hepatocytes were prepared from fresh human tissue 
and were isolated and frozen within 24 hours of organ removal. The hepatocytes 
are human transplant rejected and tested negative for hepatitis B and C and HIV 
1 and 2. Hepatocytes were thawed according to the manufacturer’s instructions 
once removed from liquid nitrogen by warming a vial of the hepatocytes at 37 °C 
for 90 seconds and suspending them in InVitroGRO HT medium (BioIVT, 
Baltimore, MD, USA) containing 1 mL TORPEDO™ Antibiotic Mix (BioIVT, 
Baltimore, MD, USA) per 45 mL media. Hepatocytes were then plated on 
Biocoat® collagen coated plates and remained cultured in this medium while 







HepG2 cell culture 
HepG2 cells were purchased from American Type Culture Collection (ATCC, 
ATCC® HB-8065™, Rockville, MD, USA). HepG2 was originally derived from a 
liver hepatocellular carcinoma in a male adolescent. The HepG2 cells were 
cultured in Dulbecco’s modified Eagle’s medium (DMEM, Gibco, Carlsbad, CA, 
USA) containing 10% fetal bovine serum (FBS, Gibco), 5.5 mM D-glucose, 1 mM 
pyruvate, and 4 mM L-glutamine, and were kept in an incubator with a humidified 
air (95%) and carbon dioxide (CO2, 5%) condition at 37 °C. 
 
Cytotoxicity assay 
For the cytotoxicity assay, HepG2 cells were treated in indicated compounds 
(MeIQ and PhIP) at the indicated concentrations (0, 0.1, 10, 100 µM) for 3 days 
in complete media. alamarBlue™ assay was used to measure cell viability.  
 
Generating NAT2 small-hairpin-loop RNA (shRNA) lentivirus 
Initially, we screened 8 different shRNA candidates for NAT2 transcript, and the 
top two candidates (shRNA4 and shRNA7) were selected for present studies. 
The target sequences for the shRNAs are the following: 5’-
GCTTGAACCTCGAACAATT-3’ for shRNA4; and 5’-
GCAGACGTCTCCAACATCT-3’ for shRNA7. The target sequence for control 
shRNA was 5’-ACTACCGTTGTTATAGGTG-3,’ which does not match any 
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known gene transcripts. The templates for the corresponding shRNAs were 
synthesized at Integrated DNA Technologies (IDT), annealed, subcloned into a 
lentiviral vector (pLenti6-U6-shRNA-GFP-2A-Puro) (unpublished, K. U. Hong), 
and sequence-verified. In pLenti6-U6-shRNA-GFP-2A-Puro vector, the human 
U6 small nuclear RNA gene promoter drives the shRNA expression while EGFP 
and puromycin resistance gene (pac) are co-expressed under SV40 promoter. 
The shRNA lentiviral vectors were then transfected into HEK 293T cells with the 
packaging mix to produce lentivirus according to manufacturer’s instructions 
(ViraPowerTM Lentiviral Expression System; Invitrogen). The lentivirus-containing 
supernatant was harvested and stored in aliquots at -80 °C.  
 
Generating NAT2 overexpression lentivirus 
The coding sequences (870 bp) for human NAT2 reference gene (NAT2*4) were 
PCR amplified using the following primers: hNAT2 fwd EcoRI, 5’-
TTTGAATTCATGGACATTGAAGCATATTTTGAAAG-3’ and hNAT2 rev XhoI, 5’-
TTCTCGAGTAATAGTAAGGGATCCATCACCAGG-3’. The PCR product was 
digested with EcoRI and XhoI and subcloned into the pLVX-2xmyc-E2A-Puro-
T2A-EGFP vector (Unpublished, K. U. Hong), a modified pLVX lentiviral vector 
(Clontech), and sequence-verified. The pLVX-2xmyc-E2A-Puro-T2A-EGFP 
utilizes viral 2A peptide sequences and allows co-expression of the gene of 
interest, plus puromycin resistance gene (pac) and EGFP from the same CMV 
promoter. The pLVX NAT2 viral construct was transfected into HEK 293T cells 
with the packaging mix to produce lentivirus according to manufacturer’s 
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instructions (ViraPowerTM Lentiviral Expression System; Invitrogen). The 
lentivirus-containing supernatant was harvested and stored in aliquots at -80 °C.  
 
Lentivirus transduction and selection 
HepG2 cells on 6-well plates were transduced with the indicated lentivirus in a 
complete media containing 6 μg/ml polybrene. After 2 days, the cells were placed 
in complete media containing 2 μg/ml puromycin to select for virus-transduced 
cells. The puromycin selection and subsequent passaging of the cells continued 
for approximately 2 weeks. Following selection, the cells were examined under a 
fluorescent microscope, and as expected, virtually every cell in the culture was 
positive for GFP. The cells were then cryo-preserved in 1 ml aliquots in cell 
freezing media (90% FBS + 10% DMSO) and stored in liquid nitrogen until use.  
 
Protein quantification and Western blot analysis 
HepG2 cells and primary human hepatocytes were lysed with Laemmli buffer (50 
mM Tris-Cl [pH 6.8], 2% sodium dodecyl sulfate [SDS; wt/vol], 0.1% 
bromophenol blue, 10% [vol/vol] glycerol) and boiled for 10 minutes. Protein 
concentrations were determined using Pierce BCA Assay kit (Thermo Scientific) 
per manufacturer’s instructions. One to two µL of 2-mercaptoethanol was added 
to each sample and boiled again for 5 minutes. Twenty-five to fifty µg of protein 
per sample was loaded and separated on 4–12% gradient Bis-Tris Plus 
polyacrylamide gels (Invitrogen). The gel was transferred to a PVDF membrane 
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and blocked in 5% (w/v) skim milk in tris buffered saline containing 0.1% Tween 
20 (TBST) for 30 minutes. Membranes were incubated with primary antibodies 
overnight at 4°C. Membranes were washed 3 times for 5 minutes each with 
TBST. Membranes were incubated for 1 hour at room temperature with 
secondary antibodies. Membranes were washed with TBST 3 times and then 




The following antibodies were purchased from Cell Signaling: phosphorylated-
protein kinase B (p-AKT S473) #4060 and protein kinase B (AKT) #4691. Α-




RNA was isolated using E.Z.N.A. Total RNA Kit 1 (OMEGA) per manufacturer’s 
protocol. cDNA was synthesized using High Capacity cDNA Reverse 
Transcriptase PCR (Thermo Fisher Scientific) per manufacturer’s instructions. 
Gene-specific cDNA was quantified with qRT-PCR using self-designed SYBR 
Green-based assays. The following primers were designed:  
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- glucose-6-phosphatase catalytic subunit (G6PC; forward: 5’-
ACGAATCTACCTTGCTGCTCA-3’; reverse: 5’-AAAATCCGATGGCGAAGCTG-
3’) 
- phosphoenolpyruvate carboxykinase 1 (PCK1 or PEPCK; forward: 5’-
TGATGAGCCGCTAGCTTCAG-3’; reverse: 5’-GCCTTTATGTTCTGCAGCCG-3’) 
- fatty acid synthase (FASN; forward: 5’-CACACACGATGGACCCTCAG-3’; 
reverse: 5’-GAAGAAGGAGAGCCGGTTGG-3’) 
-sterol regulatory element binding transcription factor 1 (SREBF1 or SREBP1; 
forward: 5’-CACCACCACCGGCGTAG-3’; reverse: 5’-
GTACCCACTGGCCTTCTCAC-3’).  
iTaq Universal SYBR Green Supermix (172–5124, Bio-Rad) was used to perform 
qRT-PCR. Reaction conditions were determined per manufacturer’s instructions. 
 
Extracellular Glucose Measurements 
Hepatocytes were seeded into Biocoat® collagen coated plates in normal media 
conditions for 24 hours to allow attachment. After 24 hours, media was replaced 
with complete media containing varying concentrations of HCAs for 2 days. 
Then, media was replaced with serum-free, glucose-free media containing 
varying concentrations of HCAs for 6 hours. After this completion, media was 
replaced in appropriate wells with serum-free, glucose-free media containing 
gluconeogenic substrates (2 mM pyruvate, 20 mM lactate, 0.5 mM L-lysine, 5 
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mM glycerol) for 24 hours. Finally, the media was collected for extracellular 
measurement of glucose and cells were harvested with Laemmli buffer for 
protein lysates for normalization to total protein content. Glucose levels were 
measured using a glucose (GO) assay kit (Sigma-Aldrich, GAGO-20). Total 
protein in each well was measured using the Pierce BCA Assay kit (Thermo 
Scientific), and the values were used to normalize the glucose levels. 
 
Statistical analysis 
Differences in gene expression among different NAT2 phenotypes and HCA 
treatments were tested for significance by One-Way or Two-Way ANOVA 
followed by Dunnett’s Multiple Comparison Test or Bonferroni’s Multiple 
Comparison Test, respectively. Statistical significance was determined per the 
following p-values: 










High-glucose model of insulin resistance in HepG2 cells. We optimized 
models that induced insulin resistance in HepG2 cells. Others have reported that 
high-glucose and high free fatty acid conditions can induce insulin resistance in 
hepatocytes [107, 108]. The high-glucose model here and the high free fatty acid 
model discussed later are used in later experiments in combination with 
heterocyclic amine (HCA) treatment and varying levels of NAT2 activity to 
determine if treatment with HCAs or changes in NAT2 activity can exacerbate 
effects of excess nutrient conditions on insulin resistance. To measure changes in 
insulin signaling in response to excess nutrients, we cultured HepG2 cells in low 
(5.5 mM) or high (25 mM) glucose-containing, serum-free media and then 
harvested for protein after 10 minutes of insulin treatment. Western blot was 
used to measure induction of p-AKT at the Ser473 site of phosphorylation. As 
mentioned previously, phosphorylation of AKT (at Thr308 and Ser473) plays a 
key role in the insulin signaling cascade [89]. Thus, we compared p-AKT 
(indicating induction of insulin signaling) to total-AKT in a p-AKT/total-AKT ratio. 
We found that cells cultured in high glucose conditions had a lower p-AKT 
induction (i.e., lower response to insulin) when compared to cells cultured in low 
glucose conditions. Consistent with previous reports [107, 108], these results 
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(Fig. 5A) indicate that high-glucose condition reduces insulin sensitivity in HepG2 
cells. 
Additionally, we confirmed our high glucose insulin resistance model by 
measuring transcripts of genes involved in gluconeogenesis (glucose-6-
phosphatase, G6PC; and phosphoenolpyruvate carboxykinase 1, PCK1). HepG2 
cells were cultured in low glucose (5.5 mM) or high glucose (25 mM) DMEM for 2 
days and then treated with 10 nM insulin for 24 hours. The samples were 
harvested for RNA and analyzed by qRT-PCR. Although insulin downregulated 
G6PC and PCK1 gene expression in high glucose, relative mRNA levels of both 
genes remain upregulated compared to low glucose with insulin (Fig. 5B). Thus, 
despite access to excess nutrients, the gluconeogenic gene transcripts are 
upregulated in these cells. These results further confirm induction of insulin 
resistance in HepG2 cells cultured with high glucose. However, insulin treatment 
should have significantly downregulated G6PC and PCK1 in low glucose 
conditions. This was not observed and indicates that our insulin treatment was 
insufficient. We are optimizing this condition by testing different insulin 






















Figure 5. High glucose model of insulin resistance in HepG2 cells. (A) Cells 
were cultured in low glucose (5.5 mM) or high glucose (25 mM) DMEM for 2 
days, then serum starved in their respective glucose conditions for 24 hours. We 
treated cells with 0, 10, or 100 nM insulin for 10 minutes prior to harvesting cells 
for protein. Western blot was used to measure p-AKT (Ser473) and total AKT 
levels. (B) Cells were cultured in low glucose (5.5 mM) or high glucose (25 mM) 
DMEM for 2 days and then treated with 10 nM insulin for 24 hours. Cells were 
then harvested for RNA and analyzed via qRT-PCR. Bars represent mean +/- 




High free fatty acid (FFA) model of insulin resistance in HepG2 cells. We 
optimized an additional model that induces insulin resistance in HepG2 cells. 
Like the high glucose model, this model is used in later experiments in 
combination with HCA treatment and varying levels of NAT2 activity to determine 
if treatment with HCAs or changes in NAT2 activity can exacerbate effects of 
excess nutrient conditions on insulin resistance. To measure changes in insulin 
signaling in response to excess FFA, we cultured HepG2 cells in DMEM 
containing 1% BSA or varying concentrations of palmitate-BSA (0.125, 0.25, 0.5 
mM) for 24 hours, then serum starved them in their respective FFA conditions for 
24 hours. We treated cells with 10 nM or 100 nM insulin for 20 minutes prior to 
harvesting them for protein. Western blot was used to measure induction of p-
AKT compared to total-AKT, as previously described. We found that cells 
cultured in high FFA conditions had a lower p-AKT induction (i.e. lower response 
to insulin) when compared to cells cultured in BSA-only conditions. These results 
(Fig. 6A) indicate that high FFA reduces insulin sensitivity in HepG2 cells in a 

























Figure 6. High free fatty acid (FFA) model of insulin resistance in HepG2 
cells.   (A) We cultured HepG2 cells in DMEM containing 1% BSA or varying 
concentrations of palmitate-BSA (0.125, 0.25, 0.5 mM) for 24 hours, then serum 
starved them in their respective FFA conditions for 24 hours. We treated cells 
with 10 nM or 100 nM insulin for 20 minutes prior to harvesting cells for protein. 










Generating shRNA cell lines to knockdown NAT2 in HepG2 cells. NAT2 is a 
highly polymorphic gene, and its SNPs produce a variety of phenotypes, 
including slow, intermediate, and rapid acetylators. To mimic the NAT2 slow 
acetylator phenotype, we generated shRNA NAT2 knockdown in HepG2 cells 
using lentiviral vectors. For our studies, we chose the top two candidates 
(shRNA4 and shRNA7) of 8 candidates screened. The templates for the 
corresponding shRNAs were synthesized, annealed, subcloned into a lentiviral 
vector, and sequence-verified. In our vector, the human U6 small nuclear RNA 
gene promoter drives the shRNA expression while EGFP and puromycin 
resistance gene (pac) are co-expressed under SV40 promoter.  Details regarding 
transfection are discussed in the Materials and Methods section of the text. 
HepG2 cells on 6-well plates were transduced with the lentivirus in a complete 
media containing 6 μg/ml polybrene. After 2 days, the cells were placed in 
complete media containing 2 µg/ml puromycin to select for virus-transduced 
cells. The puromycin selection and subsequent passaging of the cells continued 
for approximately 2 weeks. Following selection, the cells were examined under a 
fluorescent microscope (Fig. 7A), and as expected, virtually every cell in the 
culture was positive for GFP. NAT2 activity was measured in the generated cell 
lines as described in the Materials and Methods section, using sulfamethazine 
(SMZ) as a substrate to measure in situ activity (Fig. 7B). These results confirm 
that the NAT2 activity was successfully knocked down in our HepG2 NAT2 














Figure 7. Generation and characterization of HepG2 cell lines stably 
expressing control or NAT2 shRNAs. (A) Control and NAT2 shRNA HepG2 
cells were examined under a fluorescent microscope following lentiviral 
transduction and antibiotics selection. (B) NAT2 activity was measured in situ in 
HepG2 shRNA cell lines using SMZ as substrate. Bars represent mean +/- 













Generating HepG2 cell lines that overexpress NAT2. NAT2 is a highly 
polymorphic gene, and its SNPs produce a variety of phenotypes, including slow, 
intermediate, and rapid acetylators. To mimic the NAT2 rapid acetylator 
phenotype, we generated HepG2 cell lines that overexpress NAT2 using lentiviral 
vectors. Information regarding generation of lentiviral vectors and transfection 
can be found in the Methods and Materials section of this text. Cells here were 
transduced with lentivirus and selected the same as shRNA cell lines, as 
described above. Fig. 8 provides evidence of successful lentivirus-mediated 
transduction and upregulation of NAT2 activity measured by acetylation of 
sulfamethazine in situ, compared to vector control, although these initial results 
show only moderate upregulation of NAT2 activity. Additional cell lines 
overexpressing NAT2 were generated by two separate NAT2 clones (NAT2-1 













Figure 8. Generation and characterization of HepG2 cell lines stably 
expressing vector or NAT2. (A) We examined HepG2 cells under a fluorescent 
microscope following lentiviral transduction. (B) NAT2 activity was measured in 
situ in HepG2 cell lines using SMZ as substrate. Bars represent mean +/- 

























Figure 9. Generation and characterization of additional HepG2 cell lines 
stably expressing vector or NAT2. (A) We examined HepG2 cells under a 
fluorescent microscope following lentiviral transduction. (B) NAT2 activity was 
measured in situ in HepG2 cell lines using SMZ as substrate. ***, p < 0.001. Bars 
















































Significant changes in gluconeogenic and lipogenic gene expression are 
observed in HepG2 shRNA knockdown cell lines in low and high glucose 
conditions. To investigate the effects of low NAT2 activity on transcripts of 
gluconeogenic and lipogenic genes (insulin target genes), we cultured HepG2 
NAT2 shRNA cells in low (5.5 mM) and high (25 mM) glucose serum-free media 
for one day and then harvested for RNA. As previously described, 
gluconeogenesis and lipogenesis are altered with changes in metabolic function 
(glucose and lipid production). We measured gluconeogenic (G6PC, PCK1) and 
lipogenic (FASN, SREBF1) gene transcripts via qRT-PCR. Even in the absence 
of high glucose, gluconeogenic and lipogenic gene expression was 
downregulated in NAT2 shRNA cells, compared to control shRNA cells. These 
results (Figs. 10 and 11) indicate that NAT2 activity may affect regulation of 
glucose and lipid production. Additional experiments incorporating insulin into the 
















Figure 10. Gluconeogenic gene expression in control and NAT2 shRNA 
HepG2 cells (low vs. high glucose). HepG2 shRNA cell lines were cultured in 
low glucose (5.5 mM) or high glucose (25 mM) serum-free DMEM conditions for 
1 day and harvested for RNA. G6PC and PCK1 levels were measured via qRT-
PCR. (A) depicts data grouped by glucose treatment and compares control to 
NAT2 shRNA4 and shRNA7. (B) depicts data grouped by shRNA cell line and 
compares low to high glucose treatment. Statistical significance was determined 
by two-way ANOVA followed by Bonferroni’s Posttest; ***, p < 0.001. Bars 











Figure 11. Lipogenic gene expression in control and NAT2 shRNA HepG2 
cells (low vs. high glucose). HepG2 shRNA cell lines were subjected to low 
glucose (5.5 mM) or high glucose (5.5 mM) serum-free DMEM conditions for 1 
day and harvested for RNA. FASN and SREBF1 levels were measured via qRT-
PCR. (A) depicts data grouped by glucose treatment and compares control to 
NAT2 shRNA4 and shRNA7. (B) depicts data grouped by shRNA cell line and 
compares low to high glucose treatment. Statistical significance was determined 
by two-way ANOVA followed by Bonferroni’s Posttest; *, < 0.05, **, p < 0.01, ***, 











Significant changes in gluconeogenic and lipogenic gene expression are 
observed in HepG2 shRNA knockdown cell lines in the high FFA model. In 
addition to the high glucose model, the previously described high FFA model was 
used as a system of insulin resistance with the HepG2 shRNA cells. We cultured 
HepG2 shRNA NAT2 knockdown cells in 1% BSA or 0.5 mM palmitate-BSA 
serum-free media for one day and then harvested for RNA. We measured 
gluconeogenic (G6PC, PCK1) and lipogenic (FASN, SREBF1) gene expression 
via qRT-PCR. In response to high FFA, NAT2 shRNA cells showed significant 
alterations in the pattern and magnitude of gene expression. The high FFA 
treatment downregulated FASN and SREBF1 transcripts in control cells. NAT2 
shRNA cells, however, showed increases in expression of the lipogenic genes 
under the high FFA condition. In addition, PCK1 mRNA was significantly 
upregulated in high FFA-treated NAT2 shRNA cells, while the treatment did not 
affect PCK1 expression in control cells. These results (Fig. 12, Fig. 13) suggest 
that depletion of NAT2 leads to reductions in glucose and lipid production in 
HepG2 cells at both normal and excessive levels of nutrients and that 
hepatocytes expressing low NAT2 activity may be less able to effectively respond 
to the switch between fed and fasted states. Further investigation of the 
dysregulation of gluconeogenic and lipogenic genes in NAT2 knockdown cells 
will aid in understanding how NAT2 influences hepatic glucose and lipid 
homeostasis. Incorporating insulin into the experimental design will aid in 





Figure 12. Gluconeogenic gene expression in control and NAT2 shRNA 
HepG2 cells (high FFA model). HepG2 shRNA cell lines were subjected to 1% 
BSA or 0.5 mM Palmitate-BSA for 1 day and harvested for RNA. G6PC and 
PCK1 levels were measured via qRT-PCR. (A) depicts data grouped by free fatty 
acid treatment and compares control to NAT2 shRNA4 and shRNA7. (B) depicts 
data grouped by shRNA cell line and compares control (BSA) to high free fatty 
acid (PA) treatment. Statistical significance was determined by two-way ANOVA 
followed by Bonferroni’s Posttest; **, < 0.01, ***, p < 0.001. Bars represent mean 









Figure 13. Lipogenic gene expression in control and NAT2 shRNA HepG2 
cells (high FFA model). HepG2 shRNA cell lines were subjected to 1% BSA or 
0.5 mM Palmitate-BSA for 1 day and harvested for RNA. FASN and SREBF1 
levels were measured via qRT-PCR. (A) depicts data grouped by free fatty acid 
treatment and compares control to NAT2 shRNA4 and shRNA7. (B) depicts data 
grouped by shRNA cell line and compares control (BSA) to high free fatty acid 
(PA) treatment. Statistical significance was determined by two-way ANOVA 
followed by Bonferroni’s Posttest; *, p < 0.05, **, p < 0.01, ***, p < 0.001. Bars 










Cytotoxicity assay was performed in HepG2 cells to determine optimal 
concentrations of HCA treatments. We wanted to ensure HCAs would not 
result in cell death during experiments, so we tested MeIQ and PhIP, two 
common HCAs found in cooked meats [42], at different concentrations in HepG2 
cells to detect cell viability. Cells were treated with the indicated compounds at 
varying concentrations for 3 days in complete media with no media change 
during this time. alamarBlue™ assay was used to measure cell viability. There 
was relatively little to no cell death in each of the compounds tested until the 
concentration of 100 μM, where nearly half of the cells died in MeIQ (Fig.14). 
Moving forward, most experiments used a range of HCA concentrations to 
investigate dose-response, and these concentrations ranged from 0 to 100 μM, 

























Figure 14. Cell viability in HepG2 cells after treatment with MeIQ and PhIP. 
Cells were treated with either MeIQ or PhIP at concentrations of 0, 0.1, 1.0, 10, 
or 100 µM in complete media for 3 days. alamarBlue™ assay was used to 


















No statistically significant change in gluconeogenic or lipogenic gene 
expression in HepG2 cells following exposure to PhIP. HCAs are known 
human carcinogens and have recently been associated with insulin resistance 
and high serum triglycerides [100 – 103]. HCAs are produced when cooking 
meats at high temperatures or for long periods of time. Cooking method, 
temperature, type of meat, and length of cooking time impact the type of HCA 
and level present in the cooked meat [46 – 48], and this is further described in 
previous sections of this text. PhIP is the most common HCA found in cooked 
meats, though it is less genotoxic compared to other HCAs [44, 109]. To 
investigate if exposure to PhIP impacts gluconeogenic or lipogenic gene 
expression, we cultured HepG2 cells in low-glucose or high-glucose media 
containing PhIP at varying concentrations (0 – 100 μM) for 3 days and then 
harvested for RNA. The samples were analyzed by qRT-PCR to measure 
transcripts of genes involved in gluconeogenesis and lipogenesis. There were no 
statistically significant changes observed in gluconeogenic (G6PC, PCK1) or 
lipogenic (FASN, SREBF1) gene expression following exposure to PhIP at any 
concentration in either low glucose or high glucose conditions. These results 
(Fig. 15) suggest that PhIP has little impact on regulation of glucose and lipid 







Figure 15. Gluconeogenic and lipogenic gene expression in HepG2 cells 
following PhIP treatment. HepG2 cells were cultured in low glucose (5.5 mM) 
or high glucose (25 mM) DMEM and DMSO or varying concentrations (0, 1, 10 or 
100 µM) of PhIP for 3 days and then harvested for RNA. Samples were analyzed 
with qRT-PCR. Statistical significance was determined by one-way ANOVA. Bars 

















































































































































































Gluconeogenic and lipogenic gene expression in HepG2 cells is 
dysregulated by exposure to particular HCAs. To investigate the effects of 
HCAs on gluconeogenic and lipogenic gene transcription, we screened a variety 
of HCAs, including MeIQ, MeIQx, IQ, and IQx, as these are some additional 
common HCAs found in cooked meats. We cultured HepG2 cells with each HCA 
for 3 days and then harvested for RNA. The samples were analyzed by qRT-
PCR to measure transcripts of genes involved in gluconeogenesis and 
lipogenesis. We observed a variety of results among the different HCAs. G6PC 
was upregulated in MeIQx, while G6PC and SREBF1 were downregulated in IQ 
and IQx. There were no statistically significant changes in FASN among any of 
the HCAs screened compared to the control group (Fig. 16). This variety of 
results led us to believe that metabolic processes (glucose and lipid production) 
are dysregulated by HCAs, but it is currently unclear how and what is causing the 
differences in dysregulation among varying HCAs. Additionally, HepG2 cells may 
already exhibit irregular metabolic function because they are a transformed cell 
line [124]. This led to further investigation of MeIQ and MeIQ-like compounds in 





Figure 16. Gluconeogenic and lipogenic gene expression in HepG2 cells 
following HCA treatment. HepG2 cells were cultured in low glucose (5.5 mM) 
DMEM and DMSO or varying concentrations (5 or 50 µM) of MeIQ, MeIQx, IQ, or 
IQx for 3 days and then harvested for RNA. Samples were analyzed with qRT-
PCR. Statistical significance was determined by one-way ANOVA followed by 
Dunnett’s Multiple Comparison Test; *, p < 0.05, **, p < 0.01. Bars represent 











































































































































































































































































































































Dysregulation of gluconeogenic and lipogenic gene expression in HepG2 
cells in low glucose conditions following MeIQ exposure is further 
analyzed. Since the previous experiment screening several HCAs had high 
variability within experimental groups, we repeated the experiment with additional 
concentrations of MeIQ to analyze if exposure to MeIQ altered transcripts of 
G6PC, PCK1, FASN, and SREBF1. We cultured HepG2 cells in low glucose 
DMEM containing MeIQ at varying concentrations (0 – 100 µM) for 3 days and 
then harvested for RNA. The samples were analyzed by qRT-PCR to measure 
transcripts of genes involved in gluconeogenesis and lipogenesis. G6PC, PCK1, 
and FASN were significantly upregulated following MeIQ exposure. In contrast, 
SREBF1 was not significantly altered by MeIQ exposure. These results suggest 
MeIQ may directly impact steady-state glucose and lipid production in 
hepatocytes, although insulin treatment must be incorporated into the 
experimental design to measure alterations in insulin sensitivity. The statistical 
significance found in this experiment that was not apparent in the results from 









Figure 17. Gluconeogenic and lipogenic gene expression in HepG2 cells 
following MeIQ treatment. HepG2 cells were cultured in low glucose (5.5 mM) 
DMEM and DMSO or varying concentrations (0, 1, 10 or 100 µM) of MeIQ for 3 
days and then harvested for RNA. Samples were analyzed with qRT-PCR. 
Statistical significance was determined by one-way ANOVA followed by 
Dunnett’s Multiple Comparison Test; *, p < 0.05, **, p < 0.01. Bars represent 






























































































































































Changes in gluconeogenic and lipogenic gene expression in HepG2 cells 
following MeIQ exposure is not observed in the high glucose model. To 
investigate effects of MeIQ exposure on gluconeogenic and lipogenic gene 
expression in the presence of excess nutrients, we cultured HepG2 cells in high 
glucose DMEM containing MeIQ at varying concentrations (0 – 100 µM) for 3 
days and then harvested for RNA. The samples were analyzed by qRT-PCR to 
measure transcripts of genes involved in gluconeogenesis and lipogenesis. The 
changes in gene expression previously observed are no longer present in the 
high glucose model. The excess nutrients appear to overcome the previously 
observed effects of MeIQ. These results (Fig. 18) suggest that dysregulation of 
glucose and lipid production resulting from excess glucose supersede the effects 
of MeIQ observed in normal nutrient conditions, resulting in no significant 
















Figure 18. Gluconeogenic and lipogenic gene expression in HepG2 cells 
following MeIQ treatment. HepG2 cells were cultured in high glucose (25 mM) 
DMEM and DMSO or varying concentrations (1, 10 or 100 µM) of MeIQ for 3 
days and then harvested for RNA. Samples were analyzed with qRT-PCR. 
Statistical significance was determined by one-way ANOVA. Bars represent 
























































































































































MeIQ exposure significantly upregulates gluconeogenic gene transcripts 
and significantly downregulates lipogenic gene transcripts in primary 
human hepatocytes. In addition to HepG2 cells, we investigated the effects of 
HCAs on gluconeogenic and lipogenic gene transcripts in primary human 
hepatocytes, as these are more physiologically relevant and have relatively 
normal metabolic function (compared to HepG2 cells, which are transformed 
cancer cells). We cultured primary human hepatocytes in high glucose DMEM 
containing 0, 5, or 50 µM MeIQ for 3 days and then harvested for RNA. These 
samples were analyzed via qRT-PCR. G6PC and PCK1 gene transcripts were 
upregulated significantly in 5 and 50 µM MeIQ compared to the control (DMSO). 
Additionally, FASN and SREBF1 gene transcripts were significantly 
downregulated in 50 µM MeIQ. These results (Fig. 19) suggest that MeIQ 
exposure affects gluconeogenic and lipogenic gene transcript levels also in 
primary human hepatocytes. We will need to introduce insulin into the 
















Figure 19. Gluconeogenic and lipogenic gene expression in primary 
hepatocytes following MeIQ treatment. Primary human hepatocytes were 
cultured in high glucose (25 mM) DMEM with 0, 5, or 50 µM MeIQ for 3 days and 
then harvested for RNA. Samples were analyzed by qRT-PCR. Statistical 
significance was determined by one-way ANOVA followed by Tukey’s Multiple 
Comparison Test; *, p < 0.05, ***, p < 0.001. Bars represent mean +/- standard 











































































































































Insulin-induced p-AKT is reduced by MeIQ exposure in primary human 
hepatocytes. Although there was a significant difference in gluconeogenic and 
lipogenic gene transcription in primary human hepatocytes following MeIQ 
exposure, we wanted to determine if MeIQ exposure alters insulin signaling as 
well. We analyzed the effects of MeIQ on primary human hepatocytes via p-AKT 
induction (by insulin) on Western blot. Primary human hepatocytes were cultured 
with 0, 5, or 50 µM MeIQ in complete media for 2 days, then serum-starved for 
24 hours (still with MeIQ treatment in serum-free media). Hepatocytes were then 
treated with 100 nM insulin for 10 minutes. There was an apparent reduction in p-
AKT induction in response to insulin in cells treated with MeIQ (Fig. 20). These 

























Figure 20. Insulin-induced p-AKT following MeIQ treatment in primary 
hepatocytes. Primary human hepatocytes were cultured with 0, 5, or 50 µM 
MeIQ in complete media for 2 days. Hepatocytes were serum-starved with MeIQ 
treatment for 24 hours. Hepatocytes were then treated with 100 nM insulin for 10 
minutes then harvested for protein. Samples were analyzed via Western blot to 













No change in glucose production is observed in primary hepatocytes 
following MeIQ treatment. Since we observed changes in gluconeogenic gene 
expression and insulin signaling in primary hepatocytes following MeIQ 
treatment, we chose to examine if MeIQ treatment altered glucose production in 
primary hepatocytes. Hepatocytes were treated with complete media containing 
varying concentrations of MeIQ for 2 days. Then, media was replaced with 
serum-free, glucose-free media containing varying concentrations of MeIQ for 6 
hours. After completion of this period, media was replaced with serum-free, 
glucose-free media containing gluconeogenic substrates (2 mM pyruvate, 20 mM 
lactate, 0.5 mM lysine, 5 mM glycerol) for 24 hours. Finally, the media was 
collected for extracellular measurement of glucose (via glucose oxidase (GO) 
assay kit), and cells were harvested for normalization to total protein. There was 



























Figure 21. Glucose production in primary hepatocytes following MeIQ 
treatment. Primary human hepatocytes were cultured in complete media 
containing 0, 5, or 50 µM MeIQ for 2 days. Media was replaced with serum-free, 
glucose-free media containing respective concentrations of MeIQ for 6 hours. 
Media was replaced in appropriate wells with serum-free, glucose-free media 
containing gluconeogenic substrates (2 mM pyruvate, 20 mM lactate, 0.5 mM 
lysine, 5 mM glycerol) for 24 hours. Media was collected for extracellular glucose 
measurements via a glucose oxidase (GO) assay kit, and cells were harvested 






There have been recently documented associations between dietary 
heterocyclic amine (HCA) intake and insulin resistance and between N-
acetyltransferase 2 (NAT2) polymorphisms and insulin resistance [111, 112]. 
However, the association between dietary HCA intake and pathogenesis of 
insulin resistance has yet to be confirmed or directly investigated, and it is 
currently unclear the role of NAT2-mediated metabolism in this process. The 
current study investigates the effects of HCA and NAT2 phenotypes on insulin 
sensitivity and expression levels of genes involved in glucose and lipid 
metabolism in hepatocytes of human origin, including HepG2 (hepatocellular 
carcinoma) cells and cryopreserved human primary hepatocytes. Dysregulation 
of glucose and lipid production was observed in HepG2 NAT2 shRNA cell lines in 
both normal and excess nutrient conditions (Figs. 10 – 13), suggesting that NAT2 
activity levels may directly play a role in glucose and lipid homeostasis in 
hepatocytes. MeIQ, a common HCA found in cooked meat, also altered levels of 
mRNA gene transcripts of genes involved in gluconeogenesis and lipogenesis 
and reduced insulin signaling, suggesting that MeIQ may directly impact steady-
state glucose and lipid production and reduce insulin sensitivity in hepatocytes, 




HepG2 NAT2 shRNA cell lines and measuring transcripts of insulin-target 
genes 
Recently, certain genetic polymorphisms of NAT2 have been linked to 
insulin resistance, high serum triglyceride, coronary artery disease, and high 
fasting plasma glucose level [112 – 116]. Analysis of Nat1-knockout (homolog of 
human NAT2) mice revealed that Nat1 deficiency leads to development of insulin 
resistance and metabolic defects at the systemic level, supporting the previously 
unrecognized role of NAT2 in regulating metabolism and insulin sensitivity [117 – 
118]. However, it is currently unknown how NAT2 influences cellular metabolism 
and insulin sensitivity. 
In the current study, dysregulation of genes involved in glucose and lipid 
metabolism was observed in HepG2 NAT2 shRNA cell lines in both normal and 
excess nutrient conditions (high glucose and high free fatty acid) (Figs. 10-13). A 
significant reduction (p < 0.001) in transcripts of genes involved in 
gluconeogenesis (G6PC, PCK1) and lipogenesis (FASN, SREBF1) was detected 
in both NAT2 shRNA cell lines (shRNA4 and shRNA7) in low and high glucose 
conditions (Fig. 10, Fig. 11), indicating that the presence of excess nutrients was 
not required for alterations in mRNA transcript levels, but rather reduced NAT2 
activity caused the difference observed.  
The high FFA treatment, in contrast, downregulated FASN and SREBF1 
transcripts in control cells. NAT2 shRNA cells, however, showed increases in 
expression of the lipogenic genes under the high FFA condition. In addition, 
PCK1 mRNA was significantly upregulated in high FFA-treated NAT2 shRNA 
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cells, while the treatment did not affect PCK1 expression in control cells. These 
results (Figs. 12 – 13) suggest that depletion of NAT2 leads to reduction in 
glucose and lipid metabolism in HepG2 cells at both normal and excessive levels 
of nutrients and that hepatocytes expressing low NAT2 activity may be less able 
to effectively respond to the switch between fed and fasted states. Further 
investigation of the dysregulation of gluconeogenic and lipogenic genes in NAT2 
knockdown cells will aid in understanding how NAT2 influences hepatic glucose 
and lipid homeostasis. Incorporating insulin into the experimental design will aid 
in understanding how changes in NAT2 activity affect insulin sensitivity. 
Additionally, utilizing cryopreserved primary human hepatocytes with naturally 
occurring slow, intermediate, or rapid NAT2 acetylator phenotypes will provide a 
more physiologically relevant model for these experiments and translation of the 
results to human populations. 
 
PhIP treatment on HepG2 cells and measuring transcripts of insulin-target 
genes 
HCAs are produced when cooking meats at high temperatures or for long 
periods of time. Cooking method, temperature, type of meat, and length of 
cooking time impact the type of HCA and level present in the cooked meat [46 – 
48]. 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) is a common HCA 
found in cooked meats, though it is less genotoxic compared to other HCAs [44, 
109]. Though we do not know if genotoxicity of HCAs is linked to their 
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hypothesized effect on insulin sensitivity, we chose to utilize PhIP for initial 
experiments since it is the most common HCA found in cooked meat. 
In the current study, there were no statistically significant changes 
observed in gluconeogenic (G6PC, PCK1) or lipogenic (FASN, SREBF1) gene 
expression following exposure to PhIP at any concentration in either low glucose 
or high glucose conditions. These results (Fig. 15) suggest that PhIP may have 
little impact on regulation of insulin-target genes in hepatocytes. Additionally, 
previous studies investigating carcinogenic potential of HCAs largely focused on 
MeIQ and MeIQ-like compounds because they are more genotoxic in mammalian 
cells [38]. Thus. we chose to focus future experiments in this study on MeIQ and 
MeIQ-like compounds. 
 
Screening of treatment with different HCAs on HepG2 cells and measuring 
transcripts of insulin-target genes 
Several different HCAs are found in cooked meats, and the type of HCA 
and their concentrations vary depending on cooking method, temperature, type 
of meat, and length of cooking time [46 – 48]. Since no changes in transcript 
levels of insulin-target genes were observed with PhIP treatment in HepG2 cells, 
we aimed to screen additional HCAs for future experiments. 2-amino-3-
methylimidazo[4,5-ƒ]quinoline (IQ); and 2-amino-3,4-dimethylimidazo[4,5-
ƒ]quinoline (MeIQ); and their structurally related compounds 2-amino-3-
methylimidazo[4,5-f]quinoxaline (IQx); and 2-amino-3,8-dimethylimidazo[4,5-
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f]quinoxaline (8-MeIQx) were screened next, as these are additional HCAs 
frequently found in cooked meat [49 – 53]. 
In this experiment, we observed a variety of results among the different 
HCAs (Fig. 16). G6PC was upregulated in MeIQx, while G6PC and SREBF1 
were downregulated in IQ and IQx, compared to control treatment. There were 
no statistically significant changes in FASN levels among any of the HCAs 
screened compared to the control group. This variety of results led us to believe 
that metabolic processes (glucose and lipid production) are dysregulated by 
HCAs, but it is currently unclear how and what is causing the differences in 
dysregulation among varying HCAs.  
As the mechanisms by which HCAs alter insulin-target gene transcription 
remains unknown, structural differences among different HCAs may account for 
differences observed in this study [123]. Additionally, HepG2 cells may already 
exhibit irregular metabolic function because they are an immortalized cell line 
[124], and thus it is unclear if some differences seen in this study are the result of 
HepG2 model system. Moreover, we conducted experiments with MeIQ and 
MeIQ-like compounds in primary human hepatocytes to account for potential 






MeIQ treatment on HepG2 cells and measuring transcripts of insulin target 
genes 
 As previously mentioned, MeIQ and MeIQ-like compounds are HCAs 
frequently found in cooked meat [49 – 53]. Our previous study (Fig. 16) indicated 
that gluconeogenic and lipogenic gene transcripts were dysregulated with some 
of the compounds in this structural group of HCAs, so we investigated this 
phenomenon further. 
 In this study, G6PC, PCK1, and FASN transcripts were significantly 
upregulated following MeIQ exposure. In contrast, SREBF1 was not significantly 
altered by MeIQ exposure (Fig. 17). These results suggest MeIQ may impact 
steady-state glucose and lipid production in hepatocytes, although insulin 
treatment must be incorporated into the experimental design to measure 
alterations in insulin sensitivity. The statistical significance found in this 
experiment that was not apparent in the results from Figure 16 can likely be 
accredited to reduced variability within experimental groups in the current 
experiment. 
 We additionally incorporated our previously characterized high glucose 
model (Fig. 5) into our experiment with MeIQ treatment on HepG2 cells to 
evaluate if excess nutrient conditions further exacerbated the effects observed in 
normal nutrient conditions. In this study, the changes in gene expression 
previously observed (Fig. 17) are no longer present in the high glucose model 
conditions. The excess glucose appears to abolish the previously observed 
effects of MeIQ, resulting in no change between the MeIQ-treated groups and 
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control groups. Another consideration is that if both high glucose and MeIQ use 
the same pathway to induce gluconeogenic genes, then additive or synergistic 
effects may not be observed. These results (Fig. 18) suggest that dysregulation 
of glucose and lipid metabolism resulting from excess glucose supersede the 
effects of MeIQ treatment observed in normal nutrient conditions, resulting in no 
significant changes among varying MeIQ treatment concentrations, compared to 
control. It is unclear at this time why effects of MeIQ treatment observed in low 
glucose conditions are not present in high glucose conditions. However, we need 
to incorporate insulin treatment into our experimental design to measure changes 
in mRNA transcripts in response to insulin to further investigate this observation. 
 
MeIQ treatment on cryopreserved human primary hepatocytes and 
measuring transcripts of insulin-target genes 
 MeIQ treatment on HepG2 cells significantly changed mRNA levels of 
insulin target gene transcripts (Fig. 17). However, as previously mentioned, 
HepG2 cells are immortalized and thus may exhibit irregularities in metabolic 
function and glucose and lipid homeostasis [124]. Thus, we chose to additionally 
investigate effects of MeIQ treatment in cryopreserved human primary 
hepatocytes. 
 In this study, G6PC and PCK1 gene transcripts were upregulated 
significantly following treatment with 5 and 50 µM MeIQ compared to the control 
(DMSO). Additionally, FASN and SREBF1 gene transcripts were significantly 
70 
 
downregulated following treatment with 50 µM MeIQ. These results (Fig. 19) 
suggest that MeIQ alters gluconeogenic and lipogenic gene transcription in 
primary human hepatocytes, similarly to the effects observed in HepG2 cells. 
Again, we will need to introduce insulin into the experimental design to examine if 
MeIQ affects sensitivity to insulin. However, these results indicate a change in 
glucose and lipid homeostasis induced by treatment of MeIQ, further validating 
the previously observed phenomenon. 
 
MeIQ treatment on cryopreserved human primary hepatocytes and 
measuring p-AKT induction as an indicator of insulin sensitivity 
 MeIQ treatment significantly altered gluconeogenic and lipogenic gene 
transcript levels in human primary hepatocytes (Fig. 19). However, changes in 
mRNA transcripts of gluconeogenic and lipogenic genes is not adequate to 
determine insulin sensitivity. We followed up by incorporating insulin into the 
experimental design and measuring insulin-mediated induction of p-AKT, a key 
component of the insulin cascade, which is discussed in detail in the Background 
portion of this text (Fig.4). 
 In this study, there was an apparent reduction in p-AKT induction in 
response to insulin in cells treated with MeIQ (Fig. 20). These results suggest 
that MeIQ induces insulin resistance in primary human hepatocytes. However, 
these results do not indicate if there is a change in glucose production in 
response to insulin following treatment of MeIQ. Thus, a glucose production 
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assay is needed to measure the ultimate physiological effect of insulin 
resistance. 
  
MeIQ treatment on cryopreserved human primary hepatocytes and 
measuring glucose production 
 MeIQ treatment on HepG2 cells significantly changed mRNA levels of 
gene transcripts involved in insulin signaling (Fig. 17), and there was an apparent 
reduction in p-AKT induction in response to insulin in cells treated with MeIQ 
(Fig. 20). However, neither of these endpoint measurements indicate if MeIQ 
treatment results in a change of glucose production in response to insulin. Thus, 
we utilized a glucose production assay to measure extracellular glucose 
concentrations in response to insulin following treatment with MeIQ. 
 In this study, there was no detectable change in glucose production 
following treatment with MeIQ (Fig. 21). It is currently unclear as to why changes 
in gluconeogenic gene transcripts verified by a reduction in insulin signaling did 
not translate into changes in glucose production. However, this experiment still 
needs to be repeated to ensure reproducibility.  Additionally, insulin must be 
incorporated into the experimental design to determine changes in glucose 





CONCLUSIONS AND SUMMARY 
Strengths of work 
 Recently, NAT2 polymorphisms have been linked to insulin resistance, 
high serum triglyceride levels, coronary artery disease, and high fasting plasma 
glucose level [112 – 116]. A deficiency of mouse Nat1 leads to development of 
insulin resistance and metabolic defects in Nat1-knockout mice [117, 118]. 
However, thus far, all studies on this link have been conducted in murine 
systems. Using Nat1 KO mice as a surrogate for studying the effects of human 
NAT2 presents major limitations. As previously reviewed [125], the mouse Nat1 
coding sequence is only slightly more homologous to human NAT2 than to 
human NAT1, and for amino acid homology, mouse Nat1 is actually more 
homologous to human NAT1 (73%) than human NAT2 (72%). Mouse Nat1 is 
much less stable than human NAT2 [125]. Mouse Nat1 is expressed across 
every tissue examined [126], whereas human NAT2 expression is largely limited 
to liver and GI tract. Additionally, the substrate profiles of mouse Nat1 and 
human NAT2 are less similar than previously believed [127]. Therefore, it is likely 
that mouse Nat1 and human NAT2 do not share identical roles. Also, the findings 
obtained from Nat1 KO mice are limited by the fact that human NAT2 alleles that 
were reported to be linked to insulin resistance, as well as coronary artery 
disease and high triglyceride levels, are not null but functional alleles [116]. 
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Therefore, murine models of Nat1 biology may not accurately reflect the role of 
human NAT2 in insulin resistance. The present study utilizes human cell systems 
(HepG2 NAT2 shRNA cell lines) that mimic the conditions created by different 
NAT2 alleles. Thus, this study may provide a more clinically relevant depiction of 
the effects of NAT2 activity on insulin sensitivity in humans. 
 Additionally, a significant association was recently reported between HCA 
exposure via cooked meat consumption and insulin resistance after the 
multivariate analysis was adjusted for saturated fatty acid and cholesterol intake 
[111]. However, this association has yet to be confirmed in cell or animal models. 
There was a lack of laboratory studies entirely on this alleged link. Thus, this 
study reports the first findings in associations between HCA exposure and insulin 
resistance in a cell culture model. 
 Our results indicate that both level of NAT2 activity and exposure to 
certain HCAs may alter cellular glucose and lipid homeostasis. Additionally, 
these results demonstrate changes in sensitivity to insulin following exposure to 
some HCAs. These findings are significant because they indicate a genetic 
component (NAT2 polymorphism) and an environmental component (dietary 
HCA exposure via consumption in cooked meat) in the pathogenesis of insulin 
resistance in hepatocytes of human origin. As insulin resistance is a key 
component of type II diabetes mellitus and metabolic syndrome [71 – 73], these 




Limitations of work 
 The present study utilizes human cell systems (HepG2 NAT2 shRNA cell 
lines) that mimic slow acetylator NAT2 phenotype. However, additional studies 
must be conducted using HepG2 cells overexpressing NAT2, which serve to 
mimic rapid acetylator NAT2 phenotype. Moreover, as previously mentioned, 
HepG2 cells are immortalized and may not represent a physiologically accurate 
model of “normal” energy homeostasis. HepG2 cells also have naturally low 
NAT2 expression. To account for this, cryopreserved human primary hepatocytes 
that have been genotyped and grouped by rapid, intermediate, or slow NAT2 
acetylator phenotype should be used to confirm findings from experiments 
conducted with HepG2 cells. 
 Additionally, this study reports this first findings in associations between 
HCA exposure and insulin resistance in a cell culture model. However, several 
experiments presented here need to be repeated with insulin treatment 
incorporated into the experimental design so that changes in response to insulin 
may be measured. Furthermore, associations between HCA exposure and 
insulin resistance have yet to be investigated in animal models. MeIQx, the 
second most abundant HCA found in cooked meat [47], has been shown to 
cause liver tumors in animal models [128]. A previous study reported that oral 
administration of MeIQx (0.06% in food pellet) for 84 weeks in CDF1 mice 
resulted in increased frequency of hepatocellular carcinoma in male and female 
mice [128]. Similar animal models to those investigating carcinogenesis and HCA 
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exposure in mice can be applied to the studies here to analyze endpoints relating 
to insulin signaling and insulin sensitivity. 
 Lastly, and most importantly, these studies have not yet incorporated both 
NAT2 polymorphism and HCA treatment into one experimental design. The 
major metabolic pathway of HCAs includes hepatic N‑hydroxylation by CYP1A2 
followed by O-acetylation by NAT2 to form reactive oxygen species (ROS) 
leading to oxidation of lipids, proteins, and nucleic acids [129, 130]. Future 
studies should investigate both the novel link between HCA exposure to the 
development of insulin resistance and the role of NAT2-mediated metabolism in 
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further exacerbated with erlotinib/cisplatin combination treatment” 
 
Research!Louisville Poster Presentation, Louisville, KY                         
October 2018 
Department of Pharmacology and Toxicology 
“Repeated administration of cisplatin increases EGFR/EGFR activation and renal 
fibrosis in Kras4bG12D lung adenocarcinoma-bearing mice, but kidney injury is 
further exacerbated with erlotinib/cisplatin combination treatment” 
 
Cancer Education Program Poster Presentation, Louisville, KY              
August 2018 
Department of Pharmacology and Toxicology 
“Repeated administration of cisplatin increases EGFR/EGFR activation and renal 
fibrosis in Kras4bG12D lung adenocarcinoma-bearing mice, but kidney injury is 
further exacerbated with erlotinib/cisplatin combination treatment” 
 
University of Louisville Undergraduate Research Symposium                   
April 2018 
Department of Pharmacology and Toxicology  
“Repeated administration of cisplatin increases EGFR/EGFR activation and renal 
fibrosis in Kras4bG12D lung adenocarcinoma-bearing mice, but kidney injury is 




PEER REVIEWED PUBLICATIONS 
 
Hong, K. U., Doll, M. A., Lykoudi, A., Salazar-González, R. A., Habil, M. R., 
Walls, K. M., . . . Hein, D. W. (2020). Acetylator Genotype-Dependent 







WORK EXPERIENCE  
 
Walmart Pharmacy       2016-2019 






Graduate Student Regional Research Conference 
Virtual, 2021 
Attended virtually and presented orally; viewed oral and poster presentations 
 
Ohio Valley Society of Toxicology Annual Meeting 
Virtual, 2020 
Attended virtually and presented poster; viewed oral and poster presentations 
 
ACC Meeting of the Minds Annual Conference  
Louisville, KY 2019 
Attended and presented research poster; participated in networking and 
professional development seminars 
 
Society of Women Engineers Annual Conference 
Nashville, TN 2015 






American Society of Pharmacology and Experimental Therapeutics, 2020-
present 
 
Society of Toxicology, 2020-present 
 
Society of Undergraduate Chemistry Students, 2016-2019 
 












University of Louisville Undergraduate Peer Mentor Host  2015-2019 
Provide campus tours to prospective chemistry students at the University of 
Louisville 
 
VESA Student Helper       2018-2019 
Assist in distributing material to University of Louisville students about the 
Volunteer Eco Students Abroad program 
Present orally about VESA experience to prospective students   
 
GREEN Program On-Campus Ambassador    2017-2018 
Lead a recruitment campaign on the University of Louisville campus for the 
GREEN study abroad program  
Create and distribute marketing materials to provide information to students 






Volunteer Eco Students Abroad 
Volunteer, South Africa, May 2018 
Volunteer focus in conservation, education, and construction 
Built a watering hole at St. Lucia Crocodile Center, cleaned pens of savannah 
cats at The Emdoneni Cheetah Project 
Taught mathematics/English at local school in the Zulu Village, prepared lunches 
at local orphanage 




Volunteer, Thailand, July-August 2017 
Offered time and compassion to feed and bathe elephants in a sanctuary setting 






Reykjavik University Iceland School of Energy    2016 
Studied geothermal energy, hydroelectric energy, energy economics 
Toured clean energy facilities 
 
 
